We are seeking to develop transformative medicines aimed at dramatically improving the lives of patients with life-altering immune diseases.

We are evaluating an investigational study drug, TOUR006, for the treatment of Thyroid Eye Disease (TED). TED is an autoimmune disease characterized by autoantibodies that target the tissue surrounding the eye, leading to inflammation, swelling, and tissue remodeling. TED can cause significant discomfort and disfigurement, and can be sight-threatening if left untreated.


TOUR006 is a long-acting, fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory diseases. Tourmaline is developing TOUR006 towards the potential of being administered by a low volume, subcutaneous injection (not infusion) at a once every 8-week dosing interval.


The spiriTED study is evaluating an investigational study drug, TOUR006, to see how it works in adults with TED.

Trial Status: Actively recruiting

Trial Information: spiriTED is a multicenter, randomized, double-masked, placebo-controlled, dose-ranging, Phase 2b study of TOUR006 in participants with Thyroid Eye Disease

For more information, visit Identifier: NCT06088979

For information about our expanded access policy, please view here.

Learn more about TOUR006 in TED.

Learn more about the science of TOUR006.